iTeos Therapeutics Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the quarterly period endedMarch 31,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________________ to ___________________Commission File Number:001-39401 iTeos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware84-3365066(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)321 Arsenal StWatertown,MA02472(Address of principal executive offices)(Zip Code)Registrant’s telephone number, including area code: (339)217 0162 Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon stock, $0.001 par value per shareITOSNasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐ As of April 22, 2025 the registrant had38,273,795shares of common stock, $0.001 par value per share, outstanding. Summary of the material risks associated with our business Our business is subject to numerous risks and uncertainties that you should be aware of before making an investmentdecision, including those highlighted in the section entitled “Risk Factors”. These risks include, but are not limited to,the following: i•We must complete successful preclinical studies and clinical trials to demonstrate the safety, quality andefficacy of the product candidates before we can begin the commercialization process.•Challenges enrolling patients in our clinical trials may delay or prevent clinical trials of our productcandidates. Patient enrollment requires initiation of clinical trial sites; accordingly, delays in initiation of sitesexacerbate enrollment challenges.•We anticipate that our future product candidates will be used in combination with third-party drugs orbiologics and we have limited or no control over the supply, regulatory status, or regulatory approval of suchdrugs or biologics.•Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to timemay change as more patient data become available, and audit and verification procedures are required tovalidate the quality, reliability and integrity of our data and could result in material changes in the final data.•We may not be able to file investigational new drug ("IND") or clinical trial authorization ("CTA") applicationsor IND/CTA amendments to commence additional clinical trials on the timelines we expect, and, even if weare able to file, the Federal Drug Administration ("FDA") or a comparable foreign regulatory authority maynot permit us to proceed.•We face significant competition from other biopharmaceutical and biotechnology companies, academicinstitutions, government agencies, and other research organizations, which may result in others discovering,developing, or commercializing products more quickly or marketing them more successfully than us. If theirproduct candidates are shown to be safer or more effective than ours, our commercial opportunity may bereduced or eliminated.•Negative developments in the field of immuno-oncology or in the specific cancer resistance mechanisms thatwe target, such as TIGIT (as defined herein) or the adenosine pathway, could damage public perception ofour product candidates or negatively affect our business.•If we are unable to successfully commercialize any product candidate for which we receive regulatoryapproval, or experience significant delays in doing so, our